Sorry, you need to enable JavaScript to visit this website.

Exon 20 Insertion Mutations | RYBREVANT® (amivantamab-vmjw) HCP

Exon 20 insertion mutations are the third most frequent EGFR mutations1





Testing with next-generation sequencing (NGS) at diagnosis is critical to select the most appropriate, effective first-line treatment2,3




The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for NSCLC recommend testing patients to identify appropriate first-line treatment and to avoid therapies unlikely to provide clinical benefit7

Learn what makes EGFR exon 20 insertion mutations different


Patients with EGFR exon 20 insertion require a targeted clinical approach



Learn more about targeting multiple disease mechanisms in patients with EGFR exon 20 insertion mutations.

Explore how RYBREVANT® can help

CF/CT DNA, cell-free/circulating tumor DNA; DNA, deoxyribonucleic acid; EGFR, epidermal growth factor receptor; NCCN, National Comprehensive Cancer Network; NSCLC, non-small cell lung cancer.


Register for Updates

Sign up to receive the latest news and information about RYBREVANT® by completing the registration form.


1. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thoracic Oncol. 2018;13(10):1560-1568.

2. Pennell NA, Mutebi A, Zhou ZY, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non-small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1-9.

3. Vanderpoel J, Stevens AL, Emond B, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. J Med Econ. 2022;25(1):457-468.

4. Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691-4700.

5. Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531-542.

6. John A, Yang B, Shah R. Clinical impact of adherence to NCCN guidelines for biomarker testing and first-line treatment in advanced non-small cell lung cancer (aNSCLC) using real-world electronic health record data. Adv Ther. 2021;38(3):1552-1566.

7. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed March 12, 2024. To view the most recent and complete version of the guideline, go online to NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.